<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880579</url>
  </required_header>
  <id_info>
    <org_study_id>RC11_0097</org_study_id>
    <nct_id>NCT02880579</nct_id>
  </id_info>
  <brief_title>Neurothrombectomy France</brief_title>
  <acronym>NTF</acronym>
  <official_title>Evaluation of Clinical Results of Treatment of Cerebral Artery Occlusion by Mechanical Thrombectomy, in the Acute Phase of Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Ischemic Brain Vascular Accident (CVA) is a major public health issue. An Early and&#xD;
      appropriate charging anyone with stroke is essential to reduce mortality, reduce dependency&#xD;
      and promote recovery of autonomy. Intravenous fibrinolysis in patients with cerebral&#xD;
      infarction (NINDS 1995), is reserved for a small proportion of highly selected patients. It&#xD;
      therefore remains a significant therapeutic challenge, especially for patients with&#xD;
      against-indications to fibrinolysis or in whom there is no immediate benefit. For twenty&#xD;
      years of mechanical devices have been developed to remove, as quickly as possible, the cause&#xD;
      of intracranial arterial occlusion and allow restoration of blood flow before brain damage is&#xD;
      irreversible.&#xD;
&#xD;
      NTF The protocol is part of the evaluation process of our clinical practices recommended by&#xD;
      the National Health Authority (HAS), in the specific context of mechanical thrombectomy&#xD;
      performed in French centers of interventional neuroradiology working with neurovascular units&#xD;
      (A V).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>clinical score for handicap (mRS)</measure>
    <time_frame>at 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hemorrhagic complications on postoperative imaging</measure>
    <time_frame>baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemorrhagic complications on postoperative imaging</measure>
    <time_frame>at 1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physiological parameter : age</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of coronary artery disease</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of arterial hypertension</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of diabetes</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of hypercholesterolemia</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of intracranial stenosis</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of occlusive arterial disease</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of haematological disorders</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence of neoplasia</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS score</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASPECTS score</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI imaging of stroke</measure>
    <time_frame>baseline</time_frame>
    <description>Factors of good clinical prognosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unblocking rate based on the score TICI</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS evaluation</measure>
    <time_frame>at 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of collaterality score on the NIHSS</measure>
    <time_frame>at 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence ASPECTS score on the NIHSS</measure>
    <time_frame>at 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence ASPECTS score on the NIHSS</measure>
    <time_frame>at 3months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>influence of anesthesia on the NIHSS</measure>
    <time_frame>at 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemorrhagic complications</measure>
    <time_frame>at 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hemorrhagic complications on NIHSS</measure>
    <time_frame>at 24h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of hemorrhagic complications on NIHSS</measure>
    <time_frame>at 3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">230</enrollment>
  <condition>Cerebral Artery Occlusion</condition>
  <eligibility>
    <study_pop>
      <textblock>
        200 consecutive patients admitted to a stroke unit for cerebral infarction treated by&#xD;
        thrombectomy included (with or without fibrinolysis by intra venous) prospectively over a&#xD;
        period of 1 year and 3 months followed for clinical neurological assessment (primary&#xD;
        endpoint) .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signature of the information notice by the patient or his legal representative&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  Clinical and imaging consistent with ischemic stroke whose symptoms start back within&#xD;
             8h&#xD;
&#xD;
          -  Thrombosis (TICI 0 or 1) of the carotid T, M1, M1-M2 bifurcation of the basilar artery&#xD;
             occlusion in TANDEM ACI / M1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Rapid improvement of NIHSS (gain of more than 4 points) between two pre-treatment&#xD;
             assessments.&#xD;
&#xD;
          -  ASPECT score &lt;7 on the scanner or &lt;5 on the diffusion-weighted imaging (DWI)&#xD;
&#xD;
          -  Intracranial hemorrhage on imaging&#xD;
&#xD;
          -  Inability of clinical evaluations at 3 months&#xD;
&#xD;
          -  extensive lesions of the brain stem (the presence of a complete section of the&#xD;
             brainstem hyperintense b1000)&#xD;
&#xD;
          -  0 Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert DESAL, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

